
Quick Take
Neuronetics (STIM) intends to sell shares of its common stock for gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is a medical device company focused on commercializing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses.
STIM is growing topline revenues at an increasing rate and has a recurring revenue model.
However, its selling expenses as a percentage of revenues have increased sharply and the IPO valuation is not cheap.

